Skip to main content

Clinical trial


05-10-2018 | Linagliptin | EASD 2018 | News

Favorable long-term cardiovascular safety profile of linagliptin in type 2 diabetes

Findings from the CARMELINA trial suggest that the dipeptidyl peptidase-4 inhibitor linagliptin has a similar cardiovascular safety profile to placebo when added to standard care in high-risk type 2 diabetes patients.

05-10-2018 | Lorcaserin | EASD 2018 | News

Weight loss with lorcaserin linked to improved glycemic profile

Losing weight in the CAMELLIA-TIMI 61 trial was associated with a significantly reduced risk for developing type 2 diabetes, the investigators have reported at the 54th EASD Annual Meeting in Berlin, Germany.

25-09-2018 | Hypertension | News

Reweighting simulation may reconcile SPRINT, ACCORD BP findings

Research suggests that giving patients with type 2 diabetes intensive blood pressure treatment as per the ACCORD BP study would be beneficial in a real-world US population.

Read more


22-05-2019 | Sulfonylureas | Editorial | Article

The CAROLINA trial: Make or break for sulfonylureas?

Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas.

15-08-2018 | Neuropathy | Editorial | Article

Are we using the right tests to diagnose diabetic neuropathy?

Uazman Alam and colleagues interrogate current evidence and real-world clinical scenarios to address whether enough is being done with the tools available to screen and diagnose diabetic neuropathy.

19-03-2018 | Diet | View from the clinic | Article

UK nutrition guidelines: A fresh approach

Board members John Wilding and Pamela Dyson talk about the fresh approach taken to the latest update of the Diabetes UK nutrition guidelines (9:43).

In depth

16-11-2018 | Dapagliflozin | Video | Article

Researcher comment: DECLARE-TIMI 58

DECLARE-TIMI 58 steering committee member John Wilding talks us through the trial's findings (5:49).

30-09-2018 | UKPDS | Feature | Article

The UKPDS: A lasting legacy

Twenty years after the publication of the primary findings, medwireNews talks to longtime UKPDS investigator Professor David Matthews (University of Oxford, UK) about the struggles of the team to bring the trial to completion and the impact of the findings on diabetes care.

Journal articles and book chapters

08-05-2018 | Type 2 diabetes | Review | Article

Type 2 diabetes in youth: New lessons from the SEARCH study

Jensen ET, Dabelea D. Curr Diab Rep 2018; 18: 36. doi: 10.1007/s11892-018-0997-1

26-04-2018 | Obesity | Review | Article

Intermittent fasting: Is the wait worth the weight?

Stockman MC et al. Curr Obes Rep 2018; Advance online publication. doi: 10.1007/s13679-018-0308-9

27-03-2018 | Nephropathy | Review | Article

New diabetes therapies and diabetic kidney disease progression: The role of SGLT-2 inhibitors

Dekkers CCJ, Gansevoort RT, Heerspink HJL. Curr Diab Rep 2018; 18: 27. doi: 10.1007/s11892-018-0992-6

Image Credits